By BY CARL ZIMMER from NYT Health https://ift.tt/2S4aRhB
CureVac’s mRNA vaccine reaches an efficacy level of just 47 percent in a clinical trial.
By BY CARL ZIMMER from NYT Health https://ift.tt/2S4aRhB
Related Posts:
A New Covid Breath Test Holds Promise, but Wide Use May Still Be Far Off- Many Virus Cases Go Uncounted. Are There Better Ways to Track the Pandemic?
- India Is Stalling the W.H.O.’s Efforts to Make Global Covid Death Toll Public
- Many U.S. virus cases go uncounted. Are there better ways to track the pandemic?
- A New Covid Breath Test Holds Promise, but Wide Use May Still Be Far Off
0 comments:
Post a Comment